Molecular Therapeutic Advances in Personalized Therapy of Melanoma and Non-Small Cell Lung Cancer
Author:
Publisher
MDPI AG
Subject
Medicine (miscellaneous)
Link
http://www.mdpi.com/2075-4426/2/2/35/pdf
Reference64 articles.
1. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
2. Global Cancer Statistics, 2002
3. International lung cancer trends by histologic type: Male:Female differences diminishing and adenocarcinoma rates rising
4. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer;Fukouka;J. Clin. Oncol.,2003
5. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial;Kris;JAMA,2003
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Clinical Outcomes of TP53 Mutations in Cancers;Cold Spring Harbor Perspectives in Medicine;2016-07-22
2. Thérapies ciblées et mélanome : aspects pratiques et implications pour la prise en charge;Oncologie;2013-02
3. Omics and Drug Response;Annual Review of Pharmacology and Toxicology;2013-01-06
4. Targeted drug development in melanoma and nonsmall cell lung cancer: BRAF, MEK, and ALK inhibitors;memo - Magazine of European Medical Oncology;2012-11-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3